Australia's most trusted
source of pharma news
Monday, 27 July 2026
Posted 27 July 2026 AM
MSD has registered Keytruda SC, an under-the-skin version of its blockbuster PD-1 inhibitor and long time world's best-selling drug, in a key defensive move as the company prepares for biosimilar competition for its long-standing intravenous version ahead of its looming patent expiry.
Keytruda SC combines pembrolizumab with Alteogen’s berahyaluronidase alfa, an enzyme used to improve the absorption and dispersion of drugs and other agents.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.